Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 98 clinical trials
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

This phase I/II trial studies the side effects and best dose of pazopanib hydrochloride and bevacizumab and to see how well they work in treating patients with previously untreated kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells …

neutrophil count
pazopanib
clear cell renal cell carcinoma
metastatic renal cell carcinoma
measurable disease
  • 114 views
  • 25 Jan, 2021
  • 4 locations
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

This is a phase I/II open-label study designed to evaluate the combination of pembrolizumab and cabozantinib in subjects with locally advanced, recurrent, or metastatic renal cell carcinoma

pd-l1
cabozantinib
metastasis
  • 17 views
  • 25 Jan, 2021
  • 5 locations
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

objective of the trial is to determine the efficacy of combination immunotherapy of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma. The expansion phase shall address the

neutrophil count
renal function
ipilimumab
systemic therapy
platelet count
  • 83 views
  • 07 Mar, 2021
  • 20 locations
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab

This study is being done with patients with advanced kidney cancer (also called renal cell carcinoma or RCC). This is a research study involving the use of the drug Nivolumab (also known as Opdivo). Nivolumab is an anti-PD-1 antibody. It works by attaching to and blocking a molecule called PD-1. …

neutrophil count
axitinib
pazopanib
interleukin 2
ipilimumab
  • 1 views
  • 26 Jan, 2021
  • 1 location
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody PF-04518600 work in treating patients with kidney cancer that has spread to other parts of the body. Biological therapies, such as anti-OX40 antibody PF-04518600, use substances made from living organisms that may may stimulate the immune …

serum pregnancy test
neutrophil count
axitinib
white blood cells
metastatic renal cell carcinoma
  • 18 views
  • 24 Jan, 2021
  • 10 locations
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases

renal cell carcinoma (mRCC).

cabozantinib
metastasis
neutrophil count
brain metastases
  • 2 views
  • 15 Feb, 2021
  • 13 locations
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

metastatic renal cell carcinoma (RCC). This open label, nontherapeutic trial will test the correlation of 89Zr-DFO-Atezolizumab immunoPET/CT with programmed death-ligand 1 (PD-L1) expression and the response

atezolizumab
pd-l1
metastatic renal cell carcinoma
nephrectomy
programmed cell death 1 ligand 1
  • 0 views
  • 25 Jan, 2021
  • 1 location
Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial

BACKGROUND: For synchronous metastatic renal cell carcinoma (RCC), surgical resection of the primary tumor in the presence of distant metastases has been the standard of therapy for select

measurable disease
metastasis
carcinoma
ipilimumab
metastatic renal cell carcinoma
  • 0 views
  • 25 Jan, 2021
  • 3 locations
Lenvatinib and Pembrolizumab Before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer

This phase II trial studies how well lenvatinib and pembrolizumab before surgery work in treating patients with kidney cancer that has spread from its original site of growth to nearby tissues or lymph nodes but has not spread to other places in the body (non-metastatic). Lenvatinib may stop the growth …

neutrophil count
tumor cells
glomerular filtration rate
metastatic renal cell carcinoma
metastasis
  • 0 views
  • 24 Jan, 2021
Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy

FASTERCC: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy. A randomized, double-blind trial from

cancer
metastatic renal cell carcinoma
hysterectomy
  • 7 views
  • 24 Jan, 2021
  • 3 locations